Doses of Eli Lilly’s blockbuster weight loss and diabetes drugs that were listed as in short supply no longer are, according to the FDA’s database that tracks drugs in limited supply.
The agency’s shortage tracker for Mounjaro and Zepbound listed the drugs as “available” in all dosages as of Friday afternoon, though the drugs remain on the FDA’s official shortages list. Until Friday, at least four dosages of Mounjaro and Zepbound had been listed as in shortage in the US. Lilly had been struggling to produce enough of the medicines because of huge demand, particularly for anti-obesity uses.
Both drugs are based on the ingredient tirzepatide. Some doses of Wegovy, Novo Nordisk’s competing weight loss drug, remain in shortage, according to the FDA’s page.
“The FDA continues to actively monitor drug availability and work with the company to confirm the supply is stable and help ensure patient access to safe, effective drugs,” the agency said in an emailed statement.
Lilly, in an emailed statement, said the apparent improvement in supply was consistent with the company’s previous estimates.
Editor’s note: This story story has been corrected to clarify that Lilly’s drug is still on the overall shortages list.